The stock of DermTech Inc (DMTK) has seen a -1.61% decrease in the past week, with a -11.43% drop in the past month, and a -51.43% decrease in the past quarter. The volatility ratio for the week is 4.73%, and the volatility levels for the past 30 days are at 6.12% for DMTK. The simple moving average for the last 20 days is -6.55% for DMTK stock, with a simple moving average of -62.29% for the last 200 days.
Is It Worth Investing in DermTech Inc (NASDAQ: DMTK) Right Now?
Additionally, the 36-month beta value for DMTK is 2.54. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for DMTK is 30.65M and currently, short sellers hold a 10.33% ratio of that float. The average trading volume of DMTK on April 19, 2024 was 293.63K shares.
DMTK) stock’s latest price update
The stock price of DermTech Inc (NASDAQ: DMTK) has surged by 3.55 when compared to previous closing price of 0.59, but the company has seen a -1.61% decline in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-02-29 that DermTech, Inc. (DMTK) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to loss of $0.93 per share a year ago.
Analysts’ Opinion of DMTK
Many brokerage firms have already submitted their reports for DMTK stocks, with Oppenheimer repeating the rating for DMTK by listing it as a “Outperform.” The predicted price for DMTK in the upcoming period, according to Oppenheimer is $48 based on the research report published on July 18, 2022 of the previous year 2022.
BTIG Research, on the other hand, stated in their research note that they expect to see DMTK reach a price target of $19, previously predicting the price at $38. The rating they have provided for DMTK stocks is “Buy” according to the report published on June 14th, 2022.
Stephens gave a rating of “Overweight” to DMTK, setting the target price at $26 in the report published on January 07th of the previous year.
DMTK Trading at -30.25% from the 50-Day Moving Average
After a stumble in the market that brought DMTK to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -86.64% of loss for the given period.
Volatility was left at 6.12%, however, over the last 30 days, the volatility rate increased by 4.73%, as shares sank -11.94% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -49.84% lower at present.
During the last 5 trading sessions, DMTK rose by +0.80%, which changed the moving average for the period of 200-days by -79.44% in comparison to the 20-day moving average, which settled at $0.6506. In addition, DermTech Inc saw -65.03% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DMTK starting from Sun Kevin M, who sale 447 shares at the price of $1.45 back on Dec 11 ’23. After this action, Sun Kevin M now owns 277,499 shares of DermTech Inc, valued at $648 using the latest closing price.
Ibarra Claudia, the Chief Operating Officer of DermTech Inc, sale 331 shares at $1.45 during a trade that took place back on Dec 11 ’23, which means that Ibarra Claudia is holding 193,547 shares at $480 based on the most recent closing price.
Stock Fundamentals for DMTK
Current profitability levels for the company are sitting at:
- -6.78 for the present operating margin
- 0.02 for the gross margin
The net margin for DermTech Inc stands at -6.55. The total capital return value is set at -0.96. Equity return is now at value -106.46, with -62.28 for asset returns.
Based on DermTech Inc (DMTK), the company’s capital structure generated 0.49 points at debt to capital in total, while cash flow to debt ratio is standing at -1.42. The debt to equity ratio resting at 0.95. The interest coverage ratio of the stock is 133.86.
Currently, EBITDA for the company is -97.89 million with net debt to EBITDA at -0.18. When we switch over and look at the enterprise to sales, we see a ratio of 2.53. The receivables turnover for the company is 5.92for trailing twelve months and the total asset turnover is 0.13. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.59.
Conclusion
In conclusion, DermTech Inc (DMTK) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
